AKTS

Analyst Sentiment

Wall St. Consensus
Buy
7 analysts·Limited coverage
64
Score
4 Buy (57%)3 Hold (43%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
457%
Hold
343%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$30.00
+57.9%
Consensus
$30.50
+60.5%
Bull
$31.00
+63.2%
12-Month Target Range7 analysts
$30.00$30.50$31.00
Current $19.00Consensus
Current Price
$19.00
Upside to Consensus
$11.50

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+12.13%
EPS
FY2028
Rev-83.07%
EPS
FY2029
Rev+0.00%
EPS

Earnings Surprises

Recent Analyst Actions

Mar 9, 2026H.C. Wainwright
Aktis Oncology initiated with a Buy at H.C. Wainwright
Target:$30.00
+57.4%from $19.06
Feb 3, 2026Leerink Partners
Aktis Oncology initiated with an Outperform at Leerink
Target:$31.00
+41.0%from $21.98